ECHELON-1 study 3 year update: Frontline brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma

ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low-dose dexamethasone

PET after 2 cycles of ABVD in patients with early-stage favourable Hodgkin lymphoma

HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab and/or pomalidomide

Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients with R/R DLBCL and indolent lymphoma

Combination of pegcrisantaspase and venetoclax in acute myeloid leukaemia

The changing landscape of AML

Using bioinformatics and genomics to treat AML

Blinatumomab for relapsed/refractory Burkitt's lymphoma

MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma

Chemoimmunotherapy or BTK inhibition for patients with CLL

CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL